Hanmi Pharmaceutical and Beijing Hanmi Progress Clinical Trials of Co-developed BH3120 as a Next-Generation Cancer Immunotherapy
Hanmi unveils tiral in progress poster on BH3120 at the Society for Immunotherapy of Cancer (SITC) in the U.S. Phase 1 trial is progressing smoothly, with no dose-limiting toxicity observed Phase 1 trial evaluating the combination of BH3120 and MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) un...
Hanmi Unveils Novel Obesity Drug 'HM17321' : A Game-Changer in Overcoming GLP-1-Associated Muscle Loss
Fat Loss Augmentation + Lean Mass Increase Hanmi Presents Three Breakthrough Findings on Novel Obesity Drugs at 2024 ObesityWeek High Quality Obesity Management by Targeting the CRF2 Receptor: Enhanced Fat Loss with Lean Mass Increase Improved Weight Loss and Muscle Preservation with HM15275 Comb...
Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in Combination with KEYTRUDA® (pembrolizumab)
Hanmi Pharmaceutical announces Clinical Trial Collaboration with MSD to evaluate 'BH3120' in combination with KEYTRUDA in phase 1 clinical trial in patients with progressive or metastatic solid tumors SEOUL, South Korea, April 23, 2024 /PRNewswire/ -- Hanmi Pharmaceutical (KOSPI: 128940, CEO:Jae...
Hanmi Pharmaceutical's Combination Drug for Dyslipidemia Treatment, 'Rosuzet': Confirmed Non-inferiority Efficacy and Safety Compared to Monotherapy in 'The Lancet' & 'European Heart Journal'
SEOUL, South Korea, March 17, 2023 /PRNewswire/ -- Hanmi Pharmaceuticals (128940.KS), a subsidiary of Hanmi Science (008930.KS) in Korea, announced that the results of large-scale clinical trial with Rosuzet have been published in 'The Lancet' and the 'European Heart Journal'. R&D-oriented pha...
Hanmi Fine Chemical Launches 'high-tech CDMO' Business
CDMO business initiated such as mRNA vaccine raw materials·peptides 10 billion KRW invested in Hanmi Fine Chemical facility expansion SEOUL, South Korea, May 22, 2022 /PRNewswire/ -- Hanmi Fine Chemical (hereinafter Hanmi FC) a subsidiary of Hanmi Pharmaceutical Group specializing in APIs(Active...
Hanmi Pharmaceutical finds new innovative potential for "Efpeglenatide"
SEOUL, South Korea, June 29, 2021 /PRNewswire/ -- Hanmi Pharmaceutical (hereinafter Hanmi) recently announced that its new, long-acting diabetes biologic drug, efpeglenatide, was shown to significantly reduce incidences of major adverse cardiovascular events (MACE) and kidney disease in the resul...
Hanmi Pharmaceutical expects U.S. FDA approval for 2 new drugs
* Rolontis and Oraxol BLA/NDA approval from U.S. FDA is expected within this year * LAPSTriple Agonist, an innovative triple-acting new drug for NASH treatment, indication expansion * Efpeglenatide met the primary endpoint for global Phase 3 * Striving for developing rare diseases such as...
Hanmi presents solution package for coping with COVID-19, including the mass production of nucleic acid vaccines (DNA/mRNA vaccine)
SEOUL, South Korea, Jan. 13, 2021 /PRNewswire/ -- Hanmi Pharmaceutical Co., Ltd., announced "endless challenges and new commitments for the pharmaceutical industry" as their management slogan for the new year, presenting the business direction for the year 2021 at the 39th JP Morgan Healthcare...
